Could a second Clot-Buster boost stroke recovery?

NCT ID NCT05856851

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether giving the clot-busting drug alteplase directly into the brain artery, right after a mechanical thrombectomy has reopened a blocked vessel, can improve recovery from acute ischemic stroke. The study enrolls adults with large-vessel blockages in the front part of the brain, within 24 hours of symptom onset. Participants are randomly assigned to receive either standard care or standard care plus intra-arterial alteplase. The main goal is to see if more people achieve a good functional outcome (able to live independently) at 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
alteplase (a clot-busting drug) given directly into the artery after mechanical thrombectomy
What this could lead to
If effective, this could improve functional recovery and reduce disability for people who have had a major ischemic stroke, potentially changing standard post-thrombectomy care.
What could go wrong
This is a phase 3 trial, but results are not yet known. Adding a clot-buster after successful reopening of the vessel may increase bleeding risk in the brain, and benefits may not outweigh risks for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STROKE, ACUTE ISCHEMIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shenzhen Hospital of Southern Medical University

    Shenzhen, Guangdong, China

  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong, 510120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.